We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Commit to Faster End-of-Phase Meetings in Guidance to Developers
FDA to Commit to Faster End-of-Phase Meetings in Guidance to Developers
FDA released two guidance documents focusing on communications between the agency and drug developers to make drug development more efficient and to help sponsors avoid costly delays.